Upadhayay, ShubhamYedke, Narhari GangaramRahi, VikrantSingh, SurbhiKumar, SachinArora, AnchalChandolia, PriyankaKaur, PrabhsharanKumar, MandeepKoshal, PrashantJamwal, SumitKumar, Puneet2024-01-212024-08-142024-01-212024-08-142023-02-04364319010.1007/s11064-023-03868-1http://10.2.3.109/handle/32116/4357Animal models are used to better understand the various mechanisms involved in the pathogenesis of diseases and explore potential pathways that will aid in discovering therapeutic targets. 3-Nitropropionic Acid (3-NPA) is a neurotoxin used to induce Huntington's disease (HD)-like symptoms in experimental animals. The 3-NPA is a fungus toxin that impairs the complex II (succinate dehydrogenase) activity of the mitochondria and reduces ATP synthesis, leading to excessive production of free radicals resulting in the degeneration of GABAergic medium spiny neurons (MSNs) in the striatum. This is characterized by motor impairments a key clinical manifestation of HD. 3-NPA has the potential to alter several cellular processes, including mitochondrial functions, oxidative stress, apoptosis, and neuroinflammation mimicking HD-like pathogenic conditions in animals. This review strives to provide a new insight towards the 3-NPA induced molecular dysfunctioning in developing an animal model of HD. Moreover, we summarise several preclinical studies that support the use of the 3-NPA-induced models for drug discovery and development in HD. This review is a collection of various articles that were published from 1977 to 2022 on Pubmed (1639), Web of Science (2139), and Scopus (2681), which are related to the 3-NPA induced animal model. Graphical Abstract: [Figure not available: see fulltext.] � 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.en-US3-Nitropropionic acid (3-NPA)Animal ModelHuntington�s DisorderMitochondrial DysfunctionExcitotoxicityNeurodegenerationReviewhttps://link.springer.com/10.1007/s11064-023-03868-1